Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated mantle cell lymphoma in transplant-ineligible patients
jRCT2041210121Phase 3Active, not recruiting
- Sponsor
- BeiGene
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in mantle cell lymphoma (MCL) comparing Zanubrutinib plus rituximab with Bendamustine plus rituximab (2 arms). Primary endpoint: Progression-free survival. Started Jun 2021; status: active, not recruiting.
02
Drugs
zanubrutinibrituximabbendamustine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on jRCT2041210121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210121.